The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers.
about
Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosisBiomarkers of therapeutic response in multiple sclerosis: current statusNatalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosisImpact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational studyLong-term decrease in VLA-4 expression and functional impairment of dendritic cells during natalizumab therapy in patients with multiple sclerosisTherapeutic interference with leukocyte recirculation in multiple sclerosis.Effect of natalizumab on circulating CD4+ T-cells in multiple sclerosis.Treating multiple sclerosis with monoclonal antibodies: a 2013 update.TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or NatalizumabAssociation between change in normal appearing white matter metabolites and intrathecal inflammation in natalizumab-treated multiple sclerosisIntense inflammation and nerve damage in early multiple sclerosis subsides at older age: a reflection by cerebrospinal fluid biomarkers.Relationship between cerebrospinal fluid biomarkers for inflammation, demyelination and neurodegeneration in acute optic neuritisIncreased B cell and cytotoxic NK cell proportions and increased T cell responsiveness in blood of natalizumab-treated multiple sclerosis patients.Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the futureImmune and Epstein-Barr virus gene expression in cerebrospinal fluid and peripheral blood mononuclear cells from patients with relapsing-remitting multiple sclerosis.Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy.Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis.Serum Gelatinases Levels in Multiple Sclerosis Patients during 21 Months of Natalizumab Therapy.Natalizumab Treatment Modulates Peroxisome Proliferator-Activated Receptors Expression in Women with Multiple Sclerosis.Pharmacogenomics and multiple sclerosis: moving toward individualized medicine.The link between VLA-4 and JC virus reactivation.Pharmacogenomic update on multiple sclerosis: a focus on actual and new therapeutic strategies.Clinical biomarkers in multiple sclerosis.The cerebrospinal fluid in multiple sclerosis: far beyond the bands.Natalizumab discontinuation is associated with a rebound of cognitive impairment in multiple sclerosis patients.NAPS-MS: Natalizumab Effects on Parameters of Sleep in Patients with Multiple Sclerosis.Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab.Circulating CLA+ T lymphocytes as peripheral cell biomarkers in T-cell-mediated skin diseases.The role of blood and CSF biomarkers in the evaluation of new treatments against multiple sclerosis.Fluid biomarker and electrophysiological outcome measures for progressive MS trials.Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b.Cerebrospinal fluid fetuin-A is a biomarker of active multiple sclerosis.Osteopontin (OPN) as a CSF and blood biomarker for multiple sclerosis: A systematic review and meta-analysis.Understanding Progressive Multifocal Leukoencephalopathy Risk in Multiple Sclerosis Patients Treated with Immunomodulatory Therapies: A Bird's Eye View.Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy.Science is 1% inspiration and 99% biomarkers.JC Virus-DNA Detection Is Associated with CD8 Effector Accumulation in Peripheral Blood of Patients with Multiple Sclerosis under Natalizumab Treatment, Independently from JC Virus Serostatus.A Role for VAV1 in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis
P2860
Q26770818-D8E50A47-9BE9-4E7D-A626-FAA6BFEA9937Q27012726-44A8ED47-DC27-4DCA-8FB9-306CAD580964Q28484467-3D93397D-FE9C-4437-87E3-09631B3F389BQ28730321-80917805-BE2C-4344-953B-C23DB8568838Q28730755-E6B257F5-EDBB-4C08-930E-B7D3092B70DDQ30884219-7503F85C-F309-4091-872C-E9F1BD4DD6FEQ31108462-79D81768-7368-4E02-9EAF-5ADD5230E690Q34330211-D662B7F8-8CFD-4708-B5EF-7FA1229A6BB8Q34418098-50B3480D-4DC4-409E-ACD1-38F1214CDB57Q34427340-5E7DE9B1-B2C5-458B-9AD0-7943FD412873Q34718044-BCF0BAD9-DFF9-48AA-AB56-A7A9F7197607Q35015106-459D5501-8368-4EAB-90B8-A799607EACC6Q35061290-B23B85AB-DAEE-4423-845F-48C599916F20Q35078327-D3C50D35-144D-40F0-8E40-B13D6DD94480Q35848490-C7F6BF7B-DE7E-4E7E-BF21-C5C9B9531F3FQ36384476-D8624A00-D87B-4D96-A7AC-4EECB3DDAEC6Q36416627-EF29AE03-ACE3-4A45-9164-716369FE7863Q37009992-C2D51312-BA44-44D7-AC31-D93AA6DCF2A4Q37547689-45D9B878-6B31-4862-8C00-60B310801C7CQ37893991-0FFA84C2-8D2A-4C08-AB43-1CF20661CF59Q37965603-7F3EB9E7-8970-45FA-A3C9-E1CC16B309EDQ38050313-A11CEBB3-E76D-49A2-B6ED-8791AD1F82E9Q38088728-DAB800C6-6EA9-46F5-96DA-39F60277A114Q38819421-42CFCF8B-71BC-461B-8BEF-3ACAF86C0BAAQ39711019-F471C7A1-44F7-4BCD-979A-9F5B63406980Q42356708-BFA4981E-14AC-423D-AF5C-C7FB842CC57BQ44028578-46CD1268-949E-4237-B816-EB776AEBCFEBQ44759315-3D6D6C26-37E3-440B-AAE9-2396218ADDABQ47579410-715926F7-ACD0-4083-B91F-480662897C60Q47638443-7B752DCA-F7E0-4DFC-8F95-9FC519D5D242Q48132175-76968EF2-8F93-49F3-9C9D-2DD0392E881AQ48149436-C38AAF3C-D5D4-40AD-A6DC-A43A78674929Q48217814-8DDD1858-03A3-43B1-8B25-17827BF46FABQ49884884-9B48B5B8-4946-4E03-83F8-5A4221F84058Q50543805-07303157-D1B9-4ED4-B596-37D3A425A033Q50984144-8935AA24-CB18-4850-AD72-C7691598D0ECQ54230581-065E5C7D-C3CD-4904-BB8B-7B84ABA49A2AQ57224488-C34FF86A-98D7-4CA7-90F7-B57A1B965FA0
P2860
The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
The effects of natalizumab on ...... reatment-sensitive biomarkers.
@en
The effects of natalizumab on ...... reatment-sensitive biomarkers.
@nl
type
label
The effects of natalizumab on ...... reatment-sensitive biomarkers.
@en
The effects of natalizumab on ...... reatment-sensitive biomarkers.
@nl
prefLabel
The effects of natalizumab on ...... reatment-sensitive biomarkers.
@en
The effects of natalizumab on ...... reatment-sensitive biomarkers.
@nl
P2093
P50
P1476
The effects of natalizumab on ...... reatment-sensitive biomarkers.
@en
P2093
P304
P356
10.1111/J.1468-1331.2009.02532.X
P577
2009-04-01T00:00:00Z